摘要
目的总结依维莫司的药理作用,探讨其单独或联合治疗女性生殖器常见恶性肿瘤的效果,为晚期和复发转移的患者提供新的治疗思路。方法检索PubMed、Medline、中国知网、万方数据库、维普数据库有关依维莫司治疗子宫颈癌、卵巢癌和子宫内膜癌的相关文献,并结合临床现状对其进行综述。结果依维莫司能够通过多种途径阻碍肿瘤细胞的生长、代谢以及肿瘤新生血管形成等,起到抗肿瘤作用。尤其当依维莫司联合化疗、放疗、激素治疗和其他分子靶向药物时,有望克服肿瘤的耐药性,提高对肿瘤治疗的敏感性。结论依维莫司在晚期和复发转移的女性生殖器恶性肿瘤治疗中前景可观,对于提高患者预后具有很大的潜力。
OBJECTIVE To summarize the pharmacological mechanism of everolimus and to explore the effect of monotherapy or combined therapy of malignant tumors of female genital organs,and to provide a novel therapeutic ideas for patients with advanced stage,recurrence and metastasis.METHODS Retrieval of relevant literatures published in PubMed,Medline,CNKI,Wanfang and VIP databases on everolimus in the treatment of cervical cancer,ovarian cancer and endometrial cancer was conducted,and the current clinical situation was reviewed.RESULTS Everolimus can inhibit the growth,metabolism and angiogenesis of tumor cells through various ways,which plays a significant role in antitumor effects.Everolimus may overcome drug resistance and enhance tumor sensitivity to treatment,especially when combined with chemotherapy,radiotherapy,hormone therapy and other molecular targeted drugs.CONCLUSION Everolimus has promising prospects in advanced as well as advanced stage,recurrent and metastatic malignant tumors of female genital organs,with a great potential for improving patients’clinical outcomes.
作者
王喆
张颐
WANG Zhe;ZHANG Yi(Department of Gynecology,The First Hospital of China Medical University,Shenyang 110001,China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2021年第7期887-891,共5页
Chinese Journal of Modern Applied Pharmacy
基金
国家重点研发计划项目(2018YFC1311600)
辽宁省中央引导地方科技发展专项(2019JH6/10400006)
中国医科大学2019年度培育学科支持计划(妇产科学-机器人)
中国医科大学2019年度医疗新技术国际水平项目。
